InsiderClue
Stocks · Health care · Pharmaceutical Preparations

MADRIGAL PHARMACEUTICALS, INC.

MDGL Clue Score46
United States Fiscal year ends December CIK 0001157601
$471.75 -1.08% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $471.75 +479.97% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−25.2Net income−26.4Fiscal year 2017Revenue0.0Operating income−32.1Net income−31.2Fiscal year 2018Revenue0.0Operating income−40.7Net income−32.8Fiscal year 2019Revenue0.0Operating income−95.0Net income−83.9Fiscal year 2020Revenue0.0Operating income−206.7Net income−202.2EPS, diluted−13.09Fiscal year 2021Revenue0.0Operating income−242.5Net income−241.8EPS, diluted−14.63Fiscal year 2022Revenue0.0Operating income−293.6Net income−295.4EPS, diluted−17.23Fiscal year 2023Revenue0.0Operating income−380.5Net income−373.6EPS, diluted−19.99Fiscal year 2024Revenue180.1Operating income−497.9Net income−465.9EPS, diluted−21.90Fiscal year 2025Revenue958.4 +432.1%Operating income−300.1Net income−288.3EPS, diluted−12.85
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a 0.0 0.0 0.0 0.0 0.0 0.0 0.0 180.1 958.4
Growth +432.1%
Operating income −25.2 −32.1 −40.7 −95.0 −206.7 −242.5 −293.6 −380.5 −497.9 −300.1
Net income −26.4 −31.2 −32.8 −83.9 −202.2 −241.8 −295.4 −373.6 −465.9 −288.3
Growth
EPS, diluted n/a n/a n/a n/a −13.09 −14.63 −17.23 −19.99 −21.90 −12.85
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Operating margin−276.4%Net margin−258.6%Free cash flow margin−253.7%Fiscal year 2025Operating margin−31.3%Net margin−30.1%Free cash flow margin−19.8%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a n/a n/a −276.4% −31.3%
Net margin n/a n/a n/a n/a n/a n/a n/a n/a −258.6% −30.1%
Free cash flow margin n/a n/a n/a n/a n/a n/a n/a n/a −253.7% −19.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−17.6Capital expenditure−0.0Free cash flow−17.6Fiscal year 2017Operating cash flow−22.3Capital expenditure−0.1Free cash flow−22.4Fiscal year 2018Operating cash flow−25.5Capital expenditure−0.0Free cash flow−25.5Fiscal year 2019Operating cash flow−41.6Capital expenditure−0.2Free cash flow−41.8Fiscal year 2020Operating cash flow−157.6Capital expenditure−0.3Free cash flow−157.9Fiscal year 2021Operating cash flow−183.9Capital expenditure−0.2Free cash flow−184.1Fiscal year 2022Operating cash flow−224.9Capital expenditure−0.2Free cash flow−225.1Fiscal year 2023Operating cash flow−324.2Capital expenditure−1.5Free cash flow−325.7Fiscal year 2024Operating cash flow−455.6Capital expenditure−1.5Free cash flow−457.0Fiscal year 2025Operating cash flow−189.6Capital expenditure−0.5Free cash flow−190.0
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −17.6 −22.3 −25.5 −41.6 −157.6 −183.9 −224.9 −324.2 −455.6 −189.6
Capital expenditure −0.0 −0.1 −0.0 −0.2 −0.3 −0.2 −0.2 −1.5 −1.5 −0.5
Free cash flow −17.6 −22.4 −25.5 −41.8 −157.9 −184.1 −225.1 −325.7 −457.0 −190.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Cash19.1Shareholders’ equity36.4Fiscal year 2017Cash148.6Shareholders’ equity182.3Fiscal year 2018Cash57.4Shareholders’ equity477.0Fiscal year 2019Cash46.7Shareholders’ equity416.6Fiscal year 2020Cash54.0Shareholders’ equity240.0Fiscal year 2021Cash36.3Total debt0.0Net cash (debt)36.3Shareholders’ equity196.1Debt to equity0.00Fiscal year 2022Cash331.5Total debt49.3Net cash (debt)282.3Shareholders’ equity197.4Debt to equity0.25Fiscal year 2023Cash99.9Total debt115.5Net cash (debt)−15.6Shareholders’ equity405.3Debt to equity0.28Fiscal year 2024Cash100.0Total debt117.6Net cash (debt)−17.6Shareholders’ equity754.4Debt to equity0.16Fiscal year 2025Cash198.7Total debt339.9Net cash (debt)−141.2Shareholders’ equity602.7Debt to equity0.56
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 19.1 148.6 57.4 46.7 54.0 36.3 331.5 99.9 100.0 198.7
Total debt n/a n/a n/a n/a n/a 0.0 49.3 115.5 117.6 339.9
Net cash (debt) n/a n/a n/a n/a n/a 36.3 282.3 −15.6 −17.6 −141.2
Shareholders’ equity 36.4 182.3 477.0 416.6 240.0 196.1 197.4 405.3 754.4 602.7
Debt to equity n/a n/a n/a n/a n/a 0.00 0.25 0.28 0.16 0.56

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a 0.0 0.0 0.0 0.0 0.0 0.0 0.0 180.1 958.4
Growth +432.1%
n/a n/a n/a n/a n/a n/a 0.0 0.0 6.2 n/a
9.3 7.7 15.3 22.6 21.9 37.3 48.1 108.1 435.1 813.8
−25.2 −32.1 −40.7 −95.0 −206.7 −242.5 −293.6 −380.5 −497.9 −300.1
Growth
n/a n/a 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−26.4 −31.2 −32.8 −83.9 −202.2 −241.8 −295.4 −373.6 −465.9 −288.3
Growth
Per share
n/a n/a n/a n/a −13.09 −14.63 −17.23 −19.99 −21.90 −12.85
n/a n/a n/a n/a −13.09 −14.63 −17.23 −19.99 −21.90 −12.85
Growth
n/a n/a n/a n/a 15.4 16.5 17.1 18.7 21.3 22.4
n/a n/a n/a n/a 15.4 16.5 17.1 18.7 21.3 22.4
Growth +7.0% +3.6% +9.0% +13.8% +5.5%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 45.2% in five years, which is dilution.
  • A net loss in 10 of 10 years on file.